UK Markets closed

Orion Oyj (0M2N.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
34.75-0.45 (-1.28%)
At close: 3:04PM GMT
Full screen
Previous close35.20
Open35.10
Bid0.00 x 0
Ask0.00 x 0
Day's range34.75 - 35.10
52-week range34.75 - 35.10
Volume411
Avg. volumeN/A
Market cap4.459B
Beta (5Y monthly)0.50
PE ratio (TTM)22.28
EPS (TTM)1.56
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Change to the Notice of Orion Corporation’s Annual General Meeting

    ORION CORPORATION NOTICE TO ANNUAL GENERAL MEETING/STOCK EXCHANGE RELEASE 3 MARCH 2021 at 11.30 EET Change to the Notice of Orion Corporation’s Annual General Meeting The Board of Directors of Orion Corporation has decided to change the venue of Orion Corporation’s Annual General Meeting 2021 and accordingly the notice to the Annual General Meeting so that the meeting is held at Orion Corporation's Head Office, Orionintie 1, Espoo, instead of Hotel Kämp. In other respects, the notice to the Annual General Meeting published on 9 February 2021 is unchanged and the change of venue does not affect the registrations already made or the advance votes cast. The notice to the Annual General Meeting is available on Orion's website at www.orion.fi/en. Shareholders can participate in the meeting and exercise their shareholder rights either by themselves or by proxy representation only by voting in advance and by making counterproposals and presenting questions in advance in accordance with the notice to the Annual General Meeting and the Company’s other instructions. It is not possible to participate in the Annual General Meeting at the meeting venue. Shareholders can follow the Annual General Meeting over the internet via a video stream. Following the meeting over the internet via the video stream is not considered participation in the Annual General Meeting. Instructions for shareholders to participate in the Annual General Meeting as well as to follow the meeting over the internet via the video stream are presented in the notice to the Annual General Meeting. Orion Corporation Timo LappalainenPresident and CEO Olli HuotariSVP, Corporate Functions Contact person: Olli Huotari, SVP, Corporate Functionstel. +358 10 426 3054 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finland http://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

  • Globe Newswire

    Orion Group Financial Statement documents 2020, Corporate Governance Statement and Remuneration Report published

    ORION CORPORATION STOCK EXCHANGE RELEASE 2 MARCH 2021 at 11.45 EET Orion Group Financial Statement documents 2020, Corporate Governance Statement and Remuneration Report published Orion Group's Financial Statement documents for 2020 have been published. The documents are available in Finnish and English on the Company's website at http://www.orion.fi/en and are attached to this release. For the first time, the Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements as xHTML file. The primary statements of the Consolidated financial statements have been labelled with iXBRL tags. Authorised Public Accountants KPMG Oy Ab has provided an independent auditor’s reasonable assurance report on Orion’s ESEF Financial Statements in accordance with ISAE 3000 (Revised). The official Financial Statement documents in accordance with the requirements of the Finnish Accounting Act and the Companies Act, which include the Financial Statements, the Report by the Board of Directors and the Auditor's Report are available in Finnish at http://www.orion.fi/yhtiokokous2021. Orion's Corporate Governance Statement 2020 and Remuneration Report 2020, both adopted by the Board of Directors, have also been published as separate reports in Finnish and English on the Company's website at http://www.orion.fi/en and are attached to this release. Orion Corporation Olli Huotari SVP, Corporate Functions Terhi Ormio VP, Communications Contact person: Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finland http://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. Attachments Orion_Financial_Statement_Documents_2020 74370029VAHCXDR7B745-2020-12-31_en Orion_Corporate_Governance_Statement_2020 Orion_Remuneration_Report_2020

  • Globe Newswire

    Orion Corporation: Managers’ transactions – Timo Lappalainen

    ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2021 at 9.00 EET Orion Corporation: Managers’ transactions – Timo Lappalainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. ____________________________________________ Person subject to the notification requirementName: Lappalainen, TimoPosition: Chief Executive OfficerIssuer: Orion OyjLEI: 74370029VAHCXDR7B745 Notification type: INITIAL NOTIFICATIONReference number: 74370029VAHCXDR7B745_20210226102957_2____________________________________________ Transaction date: 2021-03-01Venue not applicableInstrument type: SHAREISIN: FI0009014377Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION Transaction details(1): Volume: 13,106 Unit price: 0.00000 EUR Aggregated transactions(1): Volume: 13,106 Volume weighted average price: 0.00000 EUR Orion Corporation Timo LappalainenPresident and CEO Olli HuotariSVP, Corporate Functions Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finland http://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.